MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/cells14161242

Медицинская библиотека · Cells · 2025

Chimeric Antigen Receptor T Cell Immunotherapy for Autoimmune Rheumatic Disorders: Where Are We Now?

Anyfanti Panagiota, Evangelidis Paschalis, Kotsiou Nikolaos, Papakonstantinou Anna, Eftychidis Ioannis, Sakellari Ioanna, Dimitroulas Theodoros, Gavriilaki Eleni

СтатьяОбзорПеревод в очереди

Аннотация

Chimeric antigen receptor (CAR) T cell immunotherapy has changed the landscape of B cell hematological malignancies' management, while it has recently shown promising results in the treatment of refractory autoimmune rheumatic disorders (ARDs). Targeting B cell antigens such as CD19 and BCMA, CAR-T cell therapy can induce sustained remission by the elimination of autoreactive B cell populations resistant to the standard of care treatment options. Clinical data from case reports and small case series demonstrate profound clinical responses in ARDs, including systemic lupus erythematosus (SLE), systemic sclerosis (SSc), idiopathic inflammatory myopathies (IIMs), rheumatoid arthritis (RA), antiphospholipid syndrome (APS), and primary Sjögren's syndrome (pSS). Treatment outcomes include reduced disease activity, normalization of serologic markers, improved organ function, and drug-free remission, even after B cell reconstitution. Additionally, toxicities, primarily limited to mild cytokine release syndrome (CRS), were generally manageable with supportive care. Encouraging preliminary results have led to the development of several ongoing clinical trials investigating CAR-T cell therapy across multiple ARDs and patient populations, including pediatric patients. This review summarizes the current clinical experience and provides a comprehensive overview of ongoing clinical trials exploring CAR-T cell immunotherapy for ARDs.

Для цитирования: Anyfanti Panagiota, Evangelidis Paschalis, Kotsiou Nikolaos, Papakonstantinou Anna, Eftychidis Ioannis, Sakellari Ioanna, Dimitroulas Theodoros, Gavriilaki Eleni. Chimeric Antigen Receptor T Cell Immunotherapy for Autoimmune Rheumatic Disorders: Where Are We Now?. Cells. 2025. DOI: 10.3390/cells14161242.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.